A new treatment approach for advanced prostate cancer using specialized nanoparticles
Official title: A Multimodal Hierarchical Theranostic Nanoparticle for Castration Resistant Prostate Cancer
Funded at VA Western New York Healthcare System · NIH-11098533 · Data updated 2026-11-12
This study is testing a new type of tiny particle that can help deliver cancer treatment directly to tumors in men with advanced prostate cancer, aiming to make the treatment work better and cause fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Western New York Healthcare System NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| NIH project number | 5I01BX005318-04 |
| Project ID | NIH-11098533 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer, particularly those who have undergone androgen deprivation therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have castration-resistant prostate cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel theranostic nanoparticle designed to target and treat castration-resistant prostate cancer (CRPC). The approach aims to enhance drug delivery directly to the tumor site while reducing side effects associated with systemic treatments. By utilizing advanced technology, the study seeks to improve the effectiveness of existing therapies and provide better outcomes for patients with advanced stages of prostate cancer. Patients may be monitored for their response to this innovative treatment over the course of the research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While innovative nanoparticle therapies are being explored, this specific approach targeting CRPC is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
VA Western New York Healthcare System
Buffalo, United States Active
Researchers
- Principal investigator: Schwartz, Stanley a — VA Western New York Healthcare System
- Study coordinator: Schwartz, Stanley a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.